Skip to main
VRDN
VRDN logo

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics Inc. possesses a strong outlook due to its best-in-class potential with Veligrotug, which shows comparable efficacy to existing treatments for thyroid eye disease, particularly in proptosis and diplopia reduction. The development of VRDN-003 enhances the company's competitive positioning by addressing treatment burden and expanding market presence in thyroid eye disease. Overall, the promising efficacy data and favorable safety profile of its product candidates, along with the strategic advantage of being a second-mover in the space, suggest significant advancement potential for Viridian's therapies in the current autoimmune treatment landscape.

Bears say

Viridian Therapeutics's outlook appears negative due to several fundamental concerns impacting its future performance. Key risks include the potential for decreased competitive positioning if third-party challenges arise or if intellectual property protections lapse, which could hinder the company's market share and pricing power. Additionally, uncertainties related to manufacturing processes, risk of negative trial readouts, and the high treatment burden associated with existing therapies may further complicate Viridian's ability to effectively commercialize its product candidates, limiting their market potential.

Viridian Therapeutics (VRDN) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 9 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.